• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Sarah Faulkner

For this Abbott executive, solving problems isn’t enough: ‘We need to add value’

May 3, 2018 By Sarah Faulkner

Abbott's Michael Pederson

As payers and providers across healthcare shift their focus to value-based care, leaders in the medical device industry are racing to keep up. Michael Pederson, SVP of cardiac arrhythmias and heart failure at Abbott, told MassDevice.com why simply solving problems with new technology isn’t enough anymore. What was your path like from electrical engineering to […]

Filed Under: Cardiovascular, Featured, Vascular, Wall Street Beat Tagged With: abbott

Fresenius fires back at Akorn with counterclaims following failed merger

May 3, 2018 By Sarah Faulkner

Fresenius Kabi

Fresenius (ETR:FRE) filed counterclaims against generic drugmaker Akorn Inc. (NSDQ:AKRX) this week in Delaware Chancery Court, alleging that Akorn tried to defraud the FDA with falsified testing data. Akorn filed suit against Fresenius one day after the company walked away from a $4.75 billion deal to acquire Akorn. Fresenius cited an investigation that found material breaches of […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Akorn, Fresenius

BD beats The Street with Q2 results

May 3, 2018 By Sarah Faulkner

C.R. Bard and Becton Dickinson

Shares in Becton Dickinson (NYSE: BDX) held steady today after the company beat expectations on Wall Street with its second-quarter results. The Franklin Lakes, N.J.-based company swung to a net loss of -$50 million, or -19¢ per share, on sales of $4.22 billion for the 3 months ended March 31, up 42% compared with the same period […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Becton Dickinson, C.R. Bard

Anika swings to a loss in Q1

May 3, 2018 By Sarah Faulkner

Anika Therapeutics

Shares in Anika Therapeutics (NSDQ:ANIK) fell in premarket activity today after the company missed expectations on Wall Street with its first-quarter results. The Bedford, Mass.-based company swung to a net loss of -$6.7 million, or -46¢ per share, on sales of $21.3 million for the 3 months ended March 31, down -9.1% compared with the same […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Orthopedics, Pharmaceuticals, Wall Street Beat Tagged With: Anika Therapeutics Inc.

Dexcom sales climb 30% in Q1, beating estimates on The Street

May 3, 2018 By Sarah Faulkner

Dexcom

Dexcom (NSDQ:DXCM) beat expectations on Wall Street yesterday with its first-quarter results, topping analysts’ sales estimates by $12.3 million. The San Diego, Calif.-based company posted a net loss of -$24.2 million, or -28¢, on sales of $184.4 million for the three months ended March 31, for bottom-line growth of 42% on sales growth of 30% compared […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Patient Monitoring, Pharmaceuticals, Wall Street Beat Tagged With: DexCom Inc.

Insulet inks partnerships to expand into Europe

May 2, 2018 By Sarah Faulkner

Insulet Omnipod

Insulet (NSDQ:PODD) said today that it inked deals with two partners, Theras Group and Nordic Infucare, to distribute its tubeless insulin pump, Omnipod, in Italy and the Nordic markets starting July 1. According to the agreements, both distributors will provide sales, marketing and customer support for Omnipod users and providers in Italy and the Nordic markets. […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

Intersect ENT beats The Street with Q1 sales, earnings

May 2, 2018 By Sarah Faulkner

Intersect ENT

Shares in Intersect ENT (NSDQ:XENT) held steady today after the medical device maker topped expectations on Wall Street with its first-quarter results. The Menlo Park, Calif.-based company posted a net loss of -$6.1 million, or -21¢ per share, on sales of $24.7 million for the 3 months ended March 31, for bottom-line growth of 8.8% on […]

Filed Under: Drug-Device Combinations, Featured, Implants, MassDevice Earnings Roundup, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Wall Street Beat Tagged With: Intersect ENT Inc.

Abbott’s Xience Sierra drug-eluting coronary stent wins reimbursement in Japan

May 2, 2018 By Sarah Faulkner

Abbott

Abbott (NYSE:ABT) said today that it won national reimbursement in Japan for its everolimus-eluting stent, Xience Sierra, which is designed to treat patients with coronary artery disease. The company’s latest drug-eluting device features a thinner profile, increased flexibility and longer lengths than previous stents, according to Abbott. The healthcare firm said it developed Xience Sierra to […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: abbott

J&J’s Janssen acquires cancer-killing virus tech

May 2, 2018 By Sarah Faulkner

Janssen

Johnson & Johnson‘s (NYSE:JNJ) Janssen Biotech said today that it agreed to acquire BeneVir Biopharm and its T-Stealth oncolytic virus platform. The privately-held biopharmaceutical company engineers cancer-killing viruses that are designed to infect and destroy cancer cells. Janssen plans to develop BeneVir’s preclinical candidates for the treatment of solid tumor cancers. According to the terms […]

Filed Under: Featured, Immunotherapy, Mergers & Acquisitions, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: janssen, johnsonandjohnson

NIH launches precision medicine project to collect health data from one million volunteers

May 2, 2018 By Sarah Faulkner

NIH All of Us program

The National Institutes of Health will open national enrollment next week for its All of Us research program, aiming to collect health data from at least one million volunteers across the country. The project, which has been in beta for the last year, will request health and lifestyle data from volunteers using online surveys and […]

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: National Institutes of Health

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 50
  • Page 51
  • Page 52
  • Page 53
  • Page 54
  • Interim pages omitted …
  • Page 241
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS